NASDAQ:RGC 25 September 2025 - 7 October 2025

Regencell Bioscience’s journey in 2025 has been nothing short of astonishing. The company went from an obscure penny stock to a meteoric high of $83.60 within months Stockanalysis. This 820-fold increase was “far stranger” than a typical biotech breakthrough – it happened without any major scientific news or product launch Gurufocus. Instead, a perfect storm of speculative forces sent RGC into the stratosphere. The catalyst was announced in early June: a 38-for-1 stock split. Overnight, Regencell’s share count multiplied and the price per share dropped from over $2,000 pre-split to the mid-$50s Ainvest. While a split doesn’t change a company’s intrinsic value, it does make shares more “affordable” and optionable for traders Tipranks. In Regencell’s case, the split came just as retail investor chatter was heating up. Suddenly, thousands of new traders could pile into RGC, and they did – in droves Ainvest. On June 16, the day the split took effect, volume and momentum exploded. The stock was halted repeatedly for volatility as it spiked over 200% in a single session Gurufocus Gurufocus. Over the next week, RGC kept ripping higher – at one point soaring 64,000% in just 7 days Ainvest, a jaw-dropping run that made headlines across

Regencell Bioscience’s Hong Kong office. The company is an early-stage biotech leveraging Traditional Chinese Medicine for neurological disorders. Founded in 2014 and listed on Nasdaq in 2021, Regencell focuses on developing natural TCM-based treatments for conditions like ADHD and autism spectrum disorder Marketbeat. It has even explored herbal COVID-19 remedies in the past, though these remain experimental Stocktitan. Importantly, RGC is pre-revenue – it has no product sales or FDA-approved drugs yet, and subsists on research funding and IPO proceeds. In the most recent financial report, the company disclosed zero revenue and a net loss of ~$1.85 million for the half-year ended Dec 2024 Sec. Full-year 2024 losses were about $4.4 million, indicating ongoing R&D and administrative costs. The balance sheet is modest for a company now commanding a multi-billion valuation. As of Dec 2024, Regencell held only about $6.6 million in current assets Sec and carries no long-term debt. This lean capital structure reflects that the CEO Yat-Gai Au has largely self-funded operations. The upside is no debt burden, but the downside is RGC will likely need to raise cash if it’s to advance any drug candidates – a point not lost on observers wondering how it can justify